<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Impairments in multiple cellular mechanisms increase oxidative burden in patient-derived neurons with mutations in 
 <italic>LRRK2</italic>, 
 <italic>PRKN</italic>, 
 <italic>PINK1</italic>, 
 <italic>GBA</italic>, 
 <italic>DJ-1</italic>, and 
 <italic>SNCA</italic> (20 studies)
 <sup>
  <xref ref-type="bibr" rid="CR24">24</xref>,
  <xref ref-type="bibr" rid="CR27">27</xref>–
  <xref ref-type="bibr" rid="CR29">29</xref>,
  <xref ref-type="bibr" rid="CR32">32</xref>,
  <xref ref-type="bibr" rid="CR33">33</xref>,
  <xref ref-type="bibr" rid="CR38">38</xref>,
  <xref ref-type="bibr" rid="CR40">40</xref>,
  <xref ref-type="bibr" rid="CR42">42</xref>,
  <xref ref-type="bibr" rid="CR46">46</xref>,
  <xref ref-type="bibr" rid="CR48">48</xref>,
  <xref ref-type="bibr" rid="CR53">53</xref>,
  <xref ref-type="bibr" rid="CR55">55</xref>,
  <xref ref-type="bibr" rid="CR58">58</xref>,
  <xref ref-type="bibr" rid="CR68">68</xref>,
  <xref ref-type="bibr" rid="CR77">77</xref>,
  <xref ref-type="bibr" rid="CR88">88</xref>,
  <xref ref-type="bibr" rid="CR89">89</xref>
 </sup>. Elevated basal ROS levels reported in patient-derived neurons increase cell susceptibility to cell death such that patient lines treated with oxidative and mitochondrial stressors (i.e., H
 <sub>2</sub>O
 <sub>2</sub>, rotenone and paraquat) exhibit significantly higher levels of the cell death marker caspase-3 compared with healthy controls
 <sup>
  <xref ref-type="bibr" rid="CR27">27</xref>–
  <xref ref-type="bibr" rid="CR29">29</xref>,
  <xref ref-type="bibr" rid="CR33">33</xref>,
  <xref ref-type="bibr" rid="CR39">39</xref>,
  <xref ref-type="bibr" rid="CR46">46</xref>,
  <xref ref-type="bibr" rid="CR68">68</xref>,
  <xref ref-type="bibr" rid="CR77">77</xref>,
  <xref ref-type="bibr" rid="CR88">88</xref>
 </sup>. Notably, antioxidant buffering in patient lines is reduced, marked by a low level of antioxidant enzymes and the downregulation of antioxidant pathways such as NRF2 and target gene 
 <italic>NQO1</italic>
 <sup>
  <xref ref-type="bibr" rid="CR29">29</xref>,
  <xref ref-type="bibr" rid="CR39">39</xref>,
  <xref ref-type="bibr" rid="CR77">77</xref>
 </sup>. In addition, ten studies, which did not report oxidative stress phenotypes in basal conditions, reported and increase vulnerability when oxidative stress was induced with chemicals
 <sup>
  <xref ref-type="bibr" rid="CR24">24</xref>,
  <xref ref-type="bibr" rid="CR31">31</xref>,
  <xref ref-type="bibr" rid="CR32">32</xref>,
  <xref ref-type="bibr" rid="CR40">40</xref>,
  <xref ref-type="bibr" rid="CR42">42</xref>,
  <xref ref-type="bibr" rid="CR48">48</xref>,
  <xref ref-type="bibr" rid="CR53">53</xref>,
  <xref ref-type="bibr" rid="CR55">55</xref>,
  <xref ref-type="bibr" rid="CR58">58</xref>,
  <xref ref-type="bibr" rid="CR89">89</xref>
 </sup>. This suggests that PD genetic predispositions could be compensated by upregulating endogenous antioxidant pathways or providing antioxidant supplements. Several clinical trials testing antioxidants treatments are ongoing. However, unfortunately, so far, clinical trials failed to show that antioxidants such as MitoQ significantly slow down the progression of symptoms
 <sup>
  <xref ref-type="bibr" rid="CR212">212</xref>
 </sup>. Antioxidants may need to be combined with other treatments for more positive outcomes.
</p>
